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Abstract
Introduction: Current estimates of retention among HIV-infected patients on antiretroviral therapy (ART) in Africa consider
patients who are lost to follow-up (LTF) as well as those who die shortly after their last clinic visit to be no longer in care and
to represent limitations in access to care. Yet many lost patients may have ‘‘silently’’ transferred and deaths shortly after the
last clinic visit more likely represent limitations in clinical care rather than access to care after initial linkage.
Methods: We evaluated HIV-infected adults initiating ART from 1/1/2004 to 9/30/2007 at a clinic in rural Uganda. A
representative sample of lost patients was tracked in the community to obtain updated information about care at other ART
sites. Updated outcomes were incorporated with probability weights to obtain ‘‘corrected’’ estimates of retention for the
entire clinic population. We used the competing risks approach to estimate ‘‘connection to care’’—the percentage of
patients accessing care over time (including those who died while in care).
Results: Among 3,628 patients, 829 became lost, 128 were tracked and in 111, updated information was obtained. Of 111,
79 (71%) were alive and 35/48 (73%) of patients interviewed in person were in care and on ART. Patient retention for the
clinic population assuming lost patients were not in care was 82.3%, 68.9%, and 60.1% at 1, 2 and 3 years. Incorporating
updated care information from the sample of lost patients increased estimates of patient retention to 85.8% to 90.9%,
78.9% to 86.2% and 75.8% to 84.7% at the same time points.
Conclusions: Accounting for ‘‘silent transfers’’ and early deaths increased estimates of patient retention and connection to
care substantially. Deaths soon after the last clinic visit (potentially reflecting limitations in clinical effectiveness) and
disconnection from care among patient who were alive each accounted for approximately half of failures of retention.
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Introduction
Assessing the effectiveness of the global effort to provide
antiretroviral therapy (ART) for HIV-infected patients in resource
limited settings must quantify both the number of patients
enrolling in care as well as the number of patients who continue
to access care over time [1]. Despite the importance of under-
standing engagement with ART services, however, efforts to
quantify this experience have been hampered by both conceptual
and practical barriers. First, existing estimates of retention —
which have concluded that as few as 60% of patients who start
ART in Africa are retained after two years — have been con-
ducted from the perspective of individual clinics and have assumed
that patients who are lost to follow-up (i.e., who have unknown
outcomes) are no longer engaged in care [2,3,4,5,6]. In the setting
of rapid scale up and decentralization of ART services, this
assumption may not be true. Patients who fail to return to the
clinics where they started ART may in fact have desirable out-
comes (i.e., transfers to newer and closer ART delivery sites) as
well as poor outcomes (i.e., deaths or disengagement from care)
[7]. Second, many deaths occur very shortly after the last visit to
clinic. Existing approaches combine these patients with patients
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‘‘not retained.’’ Deaths shortly after the last visit, however, are
more likely due to limitations in the effectiveness of medical care
(because of limited diagnostic or therapeutic options) and therefore
represent a different problem than disengagement from the clinic
after enrollment (potentially due to transportation, stigma, and
other socio-structural factors). Alternative analytic approaches that
are able to distinguish these early deaths after a clinic visit from
disengagement from care should be explored.
To address these barriers, first we use a sampling-based
approach to identify outcomes among those patients who are lost
to follow-up from their original ART clinic. By tracking and
obtaining updated information (e.g., vital status, continued receipt
of HIV care) from a small but representative sample of patients
who become lost to follow-up, an accurate estimate of retention in
care for all patients in the clinic population who initiate ART can
be derived. Of note, while we have previously reported the fraction
of patients among those lost to follow-up who ‘‘silently’’
transferred care to a different facility (where the denominator is
the numerically small sample of lost patients who were tracked and
interviewed) [7], in this analysis we take the next step by using the
sampling-based approach to estimate retention in care for the
entire, larger clinic population. Second, we apply a competing risk
approach estimate the percentage of patients accessing care and
which distinguishes deaths soon after the clinic visit from
disengagement from care. This estimate, which we term
‘‘connection to care,’’ is a proposed metric of the ability of
patients to attend clinic.
Methods
Ethics Statement
The study was approved by the institutional review board of
University of California, San Francisco, and the Mbarara
University of Science and Technology. The ethics approvals for
this study allow for the analysis of de-identified clinic data collected
in the course of routine care and monitoring activities, therefore
specific written or verbal consent was waived.
Patients
The patient population has been previously described [7]. In
brief, we evaluated all HIV-infected adults attending the Immune
Suppression Syndrome (ISS) Clinic in Mbarara, Uganda, who
initiated ART between January 1, 2004 and September 30, 2007.
The ISS Clinic opened on January 21, 1998, but the number of
patients was limited to less than a hundred until scale-up occurred
in 2004 and 2005, when the clinic enrolled up to 350 patients and
initiated 200 patients a month on ART. By October 1, 2007, the
total clinic enrollment had reached 12,915, and the cumulative
ART patients were 4,986. Services at the clinic are supported by
the Uganda Ministry of Health, two implementing partners of the
President’s Emergency Plan for AIDS Relief and a private
foundation (Family Treatment Fund). The clinic serves Mbarara
Municipality, which has a population of 82,000, and the rural
districts of Mbarara, Bushenyi, Ntungamo and Isingiro. These
districts cover a radius of approximately 60 km around Mbarara
Municipality with a total population of 1.7 million persons in 2006
[8].
Patients were followed from ART initiation to either death or
administrative database closure on September 30, 2007. In July
2006, the ISS Clinic began a program in which a tracker went into
the community to determine the outcomes of an unselected and
consecutive sample of patients who had become lost to follow-up.
Each month the clinic’s electronic medical record system
generated a list of patients who were lost to follow-up, defined
as not being seen at the clinic for at least 6 months. The tracker
sought to locate and directly speak with the missing patients or
close informants (e.g., family members, neighbors, or friends) in
person and in the community. A proxy was interviewed only if the
patient him or herself could not be interviewed because he/she
was living or working in a distant location or was not found at
home after repeated visits there. Given that time was limited
relative to the large number of lost patients, the tracker was unable
to search for all lost patients in all months. Therefore, effectively
only a sample of patients was sought.
Measurements
Demographic and clinical characteristics were obtained from
the ISS Clinic’s electronic medical record system. Among patients
who were lost to follow-up and found in the community by the
tracker, the clinic also administered a short structured question-
naire to determine current access to HIV care despite absence
from the ISS Clinic. Specifically, this questionnaire asked ‘‘Have
you seen a doctor or nurse for the care or treatment of HIV within the last three
months?’’ and ‘‘Have you been taking antiretroviral medications for the
treatment of HIV in the last 30 days?’’ If the patient answered
affirmatively to either question, the site of HIV care was solicited.
Patients were considered to be ‘‘in HIV care’’ if (a) they answered
affirmatively to both questions and (b) they provided a legitimate
site for both the clinic visits and the source of ART.
Statistical Analyses
We sought to estimate both ‘‘retention in care’’, defined as the
fraction of all patients starting ART who continue to be alive and
access HIV care, irrespective of clinic site, and a new parameter
termed ‘‘connection to care.’’ This new parameter is conceptually
defined as the percentage of ART initiators who either continue to
be alive and access care or who died while in care (i.e., shortly after
the last clinic visit). The motivation for estimating connection to
care is the recognition that deaths often occur despite recent
contact with an HIV clinic (i.e., despite being connected to care).
Many of the major causes of AIDS related deaths in Africa (such as
smear-negative tuberculosis, visceral Kaposi’s sarcoma, etc.) can
be difficult to diagnose without sophisticated testing capabilities
[9,10], carry high mortality even when treated [11,12], and are
therefore beyond the capacity of many new ART clinics to avert.
Conceptually, retention in care combines patients who (a) die early
after their last visit to clinic with (b) those patients who cease to
access care and who may subsequently die later. These two
outcomes, however, represent very different processes: early deaths
are due to a limitation of clinical care in most cases whereas
patients who cease coming to clinic (and who may die later
because of this lapse) do so because of stigma, transportation costs,
or other socio-structural barriers. Connection in care, therefore,
attempts to capture the fraction of patients who kept a reasonable
level of contact with ART services – even if they died despite this
contact – and therefore provides another metric of access to ART
services in Africa. When estimating both retention in care and
connection to care, we conducted a naı ¨ve analysis, which used
only data on patient outcomes that were routinely available to the
ISS Clinic through passive means, and a corrected analysis in
which we incorporated updated data on vital status and current
HIV care obtained from the sample of lost patients who were
tracked in the community.
For all time to event analyses, ART initiation was time zero. In
the naı ¨ve estimation of ‘‘retention in care,’’ the Kaplan Meier
technique was used to estimate time to failure of retention (defined
as 3 months after expected return visit or death) [13]. In the naı ¨ve
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approach [14,15,16] using competing risks was used to estimate
the occurrence of becoming ‘‘disconnected from care,’’ again
defined as being 3 months late for a return visit. However, in this
estimate, deaths that occurred within 3 months of the expected
return to clinic were treated as a competing risk. In other words,
this analysis considers disconnection from care as the event of
interest and deaths that occur shortly after the last clinic as a
competing risk because these early death alter the probability of
the event of interest. All other patients were censored at the date of
their last clinic visit.
In the corrected analyses, the same general analytic approaches
were used. Lost patients who were tracked and found to be in HIV
care at a clinic different than the ISS Clinic were censored on the
date of interview by the tracker. Lost patients who were found
alive but not in HIV care at any site were considered to have the
event of ‘‘disconnection from care’’ 3 months after their expected
return date at the ISS Clinic. If a tracked patient could not be
found in person but was deemed to be alive by report of an
informant (spouse, child, parent, neighbor, etc.), we did not ask
that informant whether the patient was still in HIV care because
this could inadvertently disclose the HIV status of the patient.
Therefore, we conducted a sensitivity analysis under a ‘‘pessimis-
tic’’ assumption that all patients who were alive but not directly
interviewed were no longer in HIV care and then under an
‘‘optimistic’’ assumption that all patients who were reported to be
alive actually remained in HIV care. All corrected estimates were
derived using sampling-based probability weights [17,18], where
outcomes in the sample of successfully tracked patients represent
outcomes in all other patients lost to follow-up. Confidence
intervals (CI) in corrected analyses were derived through boot-
strapping. Finally, we conducted a logistic regression of factors
associated with retention in care at a new site among the sample of
patients who were lost to follow-up, tracked and interviewed in
person. Socio-demographic factors associated with retention at a
significance level of ,0.1 were included in a multivariable model.
Results
Characteristics of this patient population have been previously
reported but are represented for completeness (Table 1) [7]. In
brief, a total of 3628 HIV-infected adults newly initiating ART
were evaluated. The median age was 35 years (interquartile range
(IQR) 30 to 42), and 61% were women. The median CD4+ T cell
count prior to ART in 1954 patients in whom it was available was
95 cells/mm
3 (IQR 36 to 172). The number of new patients
starting therapy was 522 in 2004, 1465 in 2005, 850 in 2006 and
796 between January 1 and September 30, 2007.
Tracking a Sample of Losses to Follow-up
Over a maximum of 3.75 years of observation, 829 patients
became lost to follow-up as defined by 6 months of absence from
the ISS Clinic. A total of 128 of the 829 patients were sought after
in the community by a tracker, and in 111 of 128 cases (87%)
updated information on vital status was obtained. Patients who
were lost and subsequently had outcomes ascertained by tracking
(n=111) were relatively similar to all patients who were lost to
follow-up in age (median 35 vs. 36 years), gender (59% vs. 58%
women), median pre-therapy CD4+ T cell count (75 vs. 72 cells/
ml), ART start date (August 30, 2005 vs. June 10
th, 2005),
Table 1. Patient characteristics.
All Patients
(Group A)
Patients Lost to
Follow-up
(Group B)
Patients Lost to
Follow-up and
Tracked (Group C)
Patients Tracked
with Vital Status
Ascertained
(Group D)
Lost Patients
Without Vital Status
Ascertainment
(Group E)
Total No. 3628 829 128 111 718
Female (%) 61 58 59 59 58
Age (years), median (IQR)* 35 (30–42) 36 (30–42) 35 (29–42) 35 (29–42) 36 (31–42)
Pre-therapy CD4 count
(cells/ml), median (IQR){
95 (36–172) 72 (19–150) 90 (20–187) 75 (20–191) 72 (19–144)
WHO stage 3 or 4 (%){ 71.9 79.5 77.3 76.6 79.9
ART start date, median (IQR) 15-Nov-05 (30-Mar-05
to 13-Nov-06)
10-Jun-05 (10-Jan-05
to 28-Oct-05)
20-Aug-05 (06-Apr-05
to 30-Oct-05)
30-Aug-05 (08-Apr-05
to 14-Nov-05)
29-Apr-05 (04-Jan-05
to 26-Oct-05)
District of residence
Bushenyi 574 (15.82) 185 (22.32) 26 (20.31) 22 (19.82) 163 (22.7)
Isingiro 428 (11.80) 49 (5.91) 9 (7.03) 8 (7.21) 41 (5.71)
Mbarara 1,790 (49.34) 358 (43.18) 70 (54.69) 61 (54.95) 297 (41.36)
Ntungamo 287 (7.91) 70 (8.44) 5 (3.91) 5 (4.5) 65 (9.05)
Other 549 (15.13) 167(20.14) 18 (14.06) 15 (13.51) 152 (21.17)
Last CD4 value before loss to
follow- up (days), median (IQR)
NA 77 (20–163) 92 (20–192) 91 (20–192) 76 (20–161)
Length on ART before loss to
follow-up (days), median (IQR)
NA 217 (15–365) 242 (36–377) 243 (29–380) 213 (14–357)
Length of time between last clinic visit
and tracking (months), median (IQR)
N/A N/A 11.8 (9.5–14.3) 12.0 (9.4–14.3) 10.8 (9.6–12.7)
*Age was missing in 30 patients.
{The last CD4 value in the 6 months before starting therapy was missing in 1954 patients.
{WHO stage at the time of initiation of ART was missing in 273 patients.
doi:10.1371/journal.pone.0021797.t001
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before lost to follow-up (91 vs. 77 cells/ml), length of time on ART
before loss in follow-up (243 vs. 217 days) and other patient
characteristics (Table 1). Among 128 lost to follow-up patients who
were tracked, the length of time between last visit and tracking was
similar for 111 patients who were successfully tracked (i.e., who
had at least updated vital status ascertained) compared to the 28
who did not (12.8 months vs. 10.8 months). Among the 111
patients whose outcomes were updated through tracking in the
community, 79/111 (71%) were found to be alive. Of these 79, 48
were directly interviewed, and 31 had information provided by an
informant.
Retention in Care and Connection to Care
Among the 48 patients whom had been deemed lost but who
were found alive and directly interviewed upon tracking in the
community, 35 (73%) indicated they were in HIV care as
evidenced by having (a) seen a provider for HIV care in the past 3
months, (b) taken ART in the 30 days, and (c) provided legitimate
sites for HIV care. The most common care site reported was The
AIDS Support Organization (TASO), where 10 patients reported
receiving care. The rest reported recently receiving care at 20
various health centers in the region. Of the remaining 13 patients
directly interviewed, 8 reported neither seeing an HIV provider in
the last 3 months nor taking ART in the last 30 days and 5
reported having made a visit to an HIV provider but that they had
not taken ART in the previous 30 days.
An estimate of retention for the entire clinic population under
the ‘‘naı ¨ve’’ assumption (that patients lost to follow-up from the
ISS clinic were no longer in HIV care), retention in care was
82.3% (95% CI: 80.9–83.7), 68.9% (95% CI: 67.1–70.8), and
60.1% (95% CI: 57.3–62.7) at 1, 2 and 3 years after ART
initiation. The estimate of retention for the clinic population
after incorporating updated care and ART status from the
sample of lost patients, but under the pessimistic assumptions of
the sensitivity analysis (that patients who were reported alive by
an informant were not in HIV care), was 85.8% (95% CI: 82.7–
88.9), 78.9% (95% CI: 75.2–82.6) and 75.8% (95% CI: 71.6–
80.1). Under the optimistic assumption in the sensitivity analysis
(that patients found alive but not interviewed in person were all
in care), retention in care for the clinic population at the same
time points was 90.9% (95% CI: 87.3–92.7), 86.2% (95% CI:
82.9–89.5) and 84.7% (95% CI: 81.0–88.5) (Figure 1 and
Table 2).
The estimate of connection to care in the clinic population
(again defined as the fraction of patients who remain in care or
who died in care) – was 83.8% (95% CI: 82.5–85.1), 70.8% (95%
CI: 68.9–72.6), and 62.0% (95% CI: 68.9–72.6) at 1, 2 and 3 years
following ART in the naı ¨ve analysis that considered all patients
lost from ISS Clinic to all be unengaged in care. In the sample-
corrected estimate, under the pessimistic assumptions of the
sensitivity analysis connection in care was estimated to be 90.9%
(95% CI: 88.1–93.8), 85.8% (95% CI: 81.9–89.8) and 83.6% (95%
CI: 79.4–87.7) at the same time points. In the sample-corrected
estimates of connection to care under the optimistic assumptions of
the sensitivity analysis, connection to care was estimated to be
95.1% (95% CI: 93.3–96.4), 93.2% (95% CI: 90.9–95.1) and
92.6% (95% CI: 89.6–94.6) at 1, 2 and 3 years (Figure 2).
Figure 1. Naı ¨ve and corrected plots of ‘‘retention in care.’’ Retention in care is defined as the fraction of patients who remain alive and in HIV
care. The naı ¨ve estimate assumes that all patients who are lost to follow-up from the ISS clinic are no longer retained in care. The corrected estimates
of retention in care are based on outcomes ascertained from a sample of patients who were lost to follow-up from the ISS Clinic, sought in the
community and in whom updated information about vital status and HIV care was obtained. If a tracked patient was found to be alive by report of an
informant, we did not ask that informant whether the patient was still in HIV care because this could inadvertently violate the privacy of the patient.
Therefore, we conducted a sensitivity analysis under two assumptions. The ‘‘pessimistic’’ corrected estimate is based on the assumption that all
patients who were alive but not directly interviewed in person were no longer in HIV care. The ‘‘optimistic’’ corrected estimate was based on the
assumption that all patients who were reported to be alive but not directly interviewed in person remained in HIV care.
doi:10.1371/journal.pone.0021797.g001
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Lost to Follow-up
Among patients who were lost to follow-up and interviewed
directly, distance between the ISS Clinic and residence was the
only factor significantly associated with the retention in care in
unadjusted analysis: each 10 km between residence and clinic
conferred a 1.30 fold rise in the odds of retention in care (95% CI,
1.04 to 1.62, p=0.02). In a multivariable analysis adjusting for
age, distance was associated with a 1.45 fold rise in the odds of
retention in care (95% CI, 1.11 to 1.90, p=0.01) and each
calendar year of last visit conferred a 4.35 fold rise in the odds of
retention in care (95% CI 1.23 to 15.4, p=0.02) (Table 3).
Discussion
This study adds to the literature assessing the impact of the
scale-up of ART services in Africa by providing a method for
estimating retention in care that accounts for the large fraction of
patients initially lost to follow-up (i.e., who have unknown
outcomes). Using this method, we found that between 78.9%
and 86.2% of the clinic patient population starting ART during
this time were retained in care two years after ART initiation. This
paints a different picture of the effectiveness of ART delivery than
our naı ¨ve estimate of 68.9% or previous work which suggested at
as few as 50% were retained at that time [2]. Although there is no
clear threshold at which retention in care is considered adequate,
these figures are disparate enough to potentially represent
‘‘failure’’ on the one hand and ‘‘success’’ on the other.
This study also proposes a metric termed ‘‘connection to care’’ that
may further the epidemiologic discourse on engagement with
ART services in Africa. Given a lack of sophisticated diagnostic or
therapeutic capabilities, some patients (such as those with smear
negative tuberculosis or malignancies) will likely die despite
engagement with the package of interventions centered on ART.
The metric of ‘‘retention in care’’ groups deaths in patients who
were essentially in care at the time of death with living patients
who cease to access care, many of who die after disengagement. As
such, it is a measure of the total effect of ART services including
Figure 2. Naı ¨ve and corrected estimates of ‘‘connection to care.’’ Connection to care uses a competing risk approach to estimate the
probability of ART initiators access care and includes patients who are alive and continuing to use the clinic as well as those died while accessing care
(i.e., who died shortly after their last clinic visit).
doi:10.1371/journal.pone.0021797.g002
Table 2. Naı ¨ve and corrected estimates of connection to care and retention in care with 95% confidence intervals.
Naı ¨ve Corrected (pessimistic) Corrected (optimistic)
Time since ART
initiation
(years) Connection to care Retention in care Connection to care Retention in care Connection to care Retention in care
1 83.8% (82.5–85.1) 82.3% (80.9–83.7) 90.9% (88.1–93.8) 85.8%(82.7–88.9) 95.1% (93.3–96.4) 90.9% (87.3–92.7)
2 70.8% (68.9–72.6) 68.9% (67.1–70.8) 85.8% (81.9–89.8) 78.9% (75.2–82.6) 93.2% (90.9–95.1) 86.2% (82.9–89.5)
3 62.0% (59.3–64.7) 60.1%(57.3–62.7) 83.6% (79.4–87.7) 75.8% (71.6–80.1) 92.6% (89.6–94.6) 84.7% (81.0–88.5)
Connection to care is defined as the fraction of ART initiators who are alive and accessing care or who died while in care. Retention in care is defined as the fraction of
ART initiators who are alive and accessing HIV care.
doi:10.1371/journal.pone.0021797.t002
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estimate of ‘‘connection to care,’’ in contrast, captures the fraction
of patients who are in care even if they died while in care (i.e.,
shortly after a clinic visit) and is therefore a more precise measure
of continued access to public health services in resource limited
settings. Although deaths shortly after the last clinic visit may be
due to a limitation of the diagnostic technologies or treatment
modalities available, these deaths are less likely attributable to a
problem with access to the ART care system once initial linkage
was established. We found approximately half of patients who
were not retained in care died before a long interval of absence
from clinic (3 months) while the other half ‘‘disconnected’’ from
care while still alive. This implies both improvement of clinical
services (at the last clinic visit) and outreach (to re-engage those out
of care) in equal measure are needed to optimize patient outcomes.
Although large implementing organizations and national pro-
grams are decentralizing ART services [19], few studies have
documented the movement of patients from older centralized to
newer and lower level ART clinics and considered the implications
of this movement on estimates of retention [20]. We found that
among those lost from the ISS Clinic in Mbarara, each additional
calendar year of last visit conferred over a 4-fold rise in the odds of
being retained in care while each 10 kilometers of distance from
residence to clinic conferred almost a 50% rise in the odds of
retention in care at another site. In the setting of southwestern
Uganda, these associations are unsurprising: while in 2000 the ISS
Clinic was the only ART delivery site in the region, by 2009 over 60
ART delivery centers had opened in southwestern Uganda. These
data are consistent with the hypothesis that high loss to follow-up is
in part due to ‘‘silent transfers’’ during the decentralization of ART
services. An alternative interpretation of these data is that losses to
follow-up at a particular clinic are due to a large extent to
incomplete penetration of ART delivery into the community.
This study has several important limitations. First, we cannot be
sure that the patients whom we deemed to be retained in care after
transferring to another clinic did not also experience a break inART
with its attendant virologic and immunologic consequences [21,22].
Research on the ‘‘safety’’ of transfers (whether silent or documented)
isurgentlyrequiredtoanswerthisquestion.Second,itispossiblethat
patients who have truly stopped ART may nonetheless report ART
use due to perceived social desirability. The tracker, however, was
not a medical provider and hence have had a more limited influence
on reporting and all patients who reported a ‘‘silent transfer’’ also
provided names of legitimate ART providers in the area – providing
some additional support for the veracity of their reports. Third, we
were unable to directly ascertain whether the 39% of patients
reported to be alive by an informant were in HIV care. Sensitivity
analysis,however,yieldedfiguresthatdeparted significantlyfrom the
naı ¨ve estimates, and hence the central inference that retention in
care is underestimated remains unchanged. Finally, our sample was
not formally random and we did not ascertain outcomes in 100% of
the sample and so our estimates may be biased.
In summary, a sampling-based approach and competing risk
analyses can provide estimates of retention in care and connection
to care among HIV-infected patients on ART in Africa where
resource limitations preclude ascertainment of outcomes in all
patients. In estimates using both pessimistic and optimistic
assumptions, we found retention in care and connection to care
in a patient population of ART users in Southwestern Uganda to
be higher than existing studies suggest. Among those lost, patients
who lived farther from the clinic and who became lost later in
calendar time were more likely to be retained in care elsewhere —
an observation consistent with the presence of ‘‘silent transfers’’
during a period of decentralization of ART services in southwest-
ern Uganda. Use of a sampling-based approach at ‘‘sentinel sites’’
or more widely within clinic based cohorts to estimate retention in
care and connection to care across diverse setting can help to
improve evaluation of the global effort to deliver ART.
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